-
Research HighlightOctober 04, 2022Defining lung cancer
Carol Bult is leading a team that has laid the groundwork for advancements in non-small cell lung cancer research using patient derived xenograft (PDX) mice. -
Featured ArticleSeptember 15, 2022JAX undertakes nationwide study to evaluate impact of genomic tumor boards on cancer care
The Jackson Laboratory announced today that it will take its cornerstone genomic tumor board program to oncologists across the nation as part of a SWOG Cancer Research Network study, in collaboration with Columbia University. -
Research HighlightAugust 01, 2022Researching facilitators of cancer metastasis
Guangwen “Gary” Ren's new research shows that the structural cells in the lung (fibroblasts) drive myeloid cell dysfunction to create a more welcoming environment for metastatic cancer. -
Featured ArticleJune 28, 2022JAX Genomic Medicine is increasing the precision of brain cancer diagnoses
The new technique of methylome profiling, now available from The Jackson Laboratory, provides more precise tumor classification for cancers of the central nervous system (CNS).
-
Research HighlightSeptember 28, 2022Tipping the scale toward favorable outcomes in cancer and beyond
Jennifer Trowbridge and her team reveal the molecular signaling pathway most associated with clonal hematopoiesis and how blocking a specific cell-surface receptor in the pathway can tip the balance toward positive health outcomes. -
Featured ArticleAugust 02, 2022Eric Wang is overcoming treatment resistance in leukemia
Eric Wang joins the JAX faculty to devise new strategies to overcome the development of drug resistance in cancer. -
Research HighlightJuly 07, 2022JAX team discovers mechanism for chemotherapy resistance
A team led by JAX's Edison Liu and Francesca Menghi used patient data, patient-derived xenograft (PDX) mouse models, and engineered cancer cell lines to investigate why people with BRCA mutations respond better and are less likely to develop platinum-based therapy resistance than patients with BRCA1 promoter methylation. -
Press ReleaseJune 22, 2022JAXs Roel Verhaak joins global Cancer Grand Challenges team
Roel Verhaak has joined the global Cancer Grand Challenges team, receiving $25M to take on the challenge of extrachromosomal DNA.